S. Lehto

发表

Correlation between brain/plasma ratios and efficacy in neuropathic pain models of selective metabotropic glutamate receptor 1 antagonists.

Jill M. Wetter, J. Brioni, S. Baker, 2006, Bioorganic & medicinal chemistry letters.

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

S. Lehto, D. Immke, K. Wild, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Antihyperalgesic Effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a Novel Transient Receptor Potential Vanilloid Type 1 Modulator That Does Not Cause Hyperthermia in Rats

J. Louis, B. H. Manning, N. Gavva, 2008, Journal of Pharmacology and Experimental Therapeutics.

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.

Stephanie D. Geuns-Meyer, N. Gavva, Y. Teffera, 2016, Journal of medicinal chemistry.

Electrophysiological and in vivo characterization of A-317567, a novel blocker of acid sensing ion channels

G. Dubé, J. Brioni, S. Baker, 2005, Pain.

A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.

Stanley B. Cohen, D. Niederwieser, V. Hanes, 2022, Immunotherapy.

Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats.

J. Brioni, S. Baker, R. Moreland, 2008, European journal of pharmacology.

Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene.

E. Chesler, M. Devor, K. Messlinger, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states.

S. Baker, C. Surowy, P. Honore, 2008, The journal of pain : official journal of the American Pain Society.

AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia

C. Stucky, N. Gavva, Andy D. Weyer, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse

J. Mogil, K. Young, Amanda D. Green, 2006, Pain.

Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.

Meena Patel, M. Nakane, J. Brioni, 2005, Journal of medicinal chemistry.

Fused piperidines as a novel class of potent and orally available transient receptor potential melastatin type 8 (TRPM8) antagonists.

M. Bartberger, Yunxin Y Bo, N. Gavva, 2012, Journal of medicinal chemistry.

Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists.

L. Arik, R. Fremeau, M. Bryan, 2011, Journal of medicinal chemistry.

Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists.

H. Monenschein, M. Bartberger, Yunxin Y Bo, 2014, Journal of medicinal chemistry.

TRPV1 antagonists that cause hypothermia, instead of hyperthermia, in rodents: Compounds’ pharmacological profiles, in vivo targets, thermoeffectors recruited and implications for drug development

A. A. Romanovsky, A. Gomtsyan, E. Pintér, 2018, Acta physiologica.

The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation

J. Treanor, T. Juan, J. Louis, 2007, The Journal of Neuroscience.

Chromenones as potent bradykinin B1 antagonists.

L. Arik, R. Fremeau, R. Rzasa, 2012, Bioorganic & medicinal chemistry letters.

Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain

A. Malmberg, K. Clarkin, T. Juan, 2010, PAIN®.

Crystal structures of human glycine receptor α3 bound to a novel class of analgesic potentiators

J. Luther, H. Bregman, Xin Huang, 2016, Nature Structural &Molecular Biology.

AMG2850, a potent and selective TRPM8 antagonist, is not effective in rat models of inflammatory mechanical hypersensitivity and neuropathic tactile allodynia

C. Stucky, N. Gavva, Andy D. Weyer, 2015, Naunyn-Schmiedeberg's Archives of Pharmacology.

Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A‐841720, a novel non‐competitive mGluR1 receptor antagonist

G. Fox, S. Baker, M. Mezler, 2006, British journal of pharmacology.

Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7

Dong Liu, J. Luther, R. Fremeau, 2017, The Journal of Pharmacology and Experimental Therapeutics.

A review of current animal models of osteoarthritis pain.

W. Tsuji, S. Lehto, Warren N D'Souza, 2011, Current pharmaceutical biotechnology.

Transient Receptor Potential Channel Ankyrin-1 Is Not a Cold Sensor for Autonomic Thermoregulation in Rodents

A. A. Romanovsky, V. Tékus, K. Pohóczky, 2014, The Journal of Neuroscience.

Selective antagonism of TRPA1 produces limited efficacy in models of inflammatory- and neuropathic-induced mechanical hypersensitivity in rats

C. Stucky, B. Moyer, Stephanie D. Geuns-Meyer, 2016, Molecular pain.

Development of TRPM8 Antagonists to Treat Chronic Pain and Migraine

Andy D. Weyer, S. Lehto, 2017, Pharmaceuticals.

PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?

Hantao Liu, P. Goadsby, B. Moyer, 2020, Pain.

Discovery of TRPM8 Antagonist ( S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine.

H. Monenschein, M. Horner, M. Bartberger, 2018, Journal of medicinal chemistry.

Voltage-gated sodium channel function and expression in injured and uninjured rat dorsal root ganglia neurons

B. Moyer, Yi Luo, S. Lehto, 2016, The International journal of neuroscience.

Development of novel azabenzofuran TRPA1 antagonists as in vivo tools.

Stephanie D. Geuns-Meyer, N. Gavva, A. Boezio, 2014, Bioorganic & medicinal chemistry letters.

Repeated Administration of Vanilloid Receptor TRPV1 Antagonists Attenuates Hyperthermia Elicited by TRPV1 Blockade

J. Treanor, L. Arik, C. Henley, 2007, Journal of Pharmacology and Experimental Therapeutics.

Transient receptor potential melastatin 8 (TRPM8) channels are involved in body temperature regulation

N. Gavva, S. Lehto, C. Davis, 2012, Molecular pain.

TRPV1 modulator that does not cause hyperthermia in rats

J. Louis, B. H. Manning, N. Gavva, 2008 .

The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors.

H. Bregman, Xin Huang, Liyue Huang, 2017, Journal of medicinal chemistry.

EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor

S. Lehto, D. Immke, K. Wild, 2014, The Journal of Headache and Pain.

Rat NaV1.7 loss-of-function genetic model: Deficient nociceptive and neuropathic pain behavior with retained olfactory function and intra-epidermal nerve fibers

S. Waxman, B. Moyer, Dong Liu, 2019, Molecular pain.

Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain

A. Malmberg, K. Clarkin, T. Juan, 2010, PAIN®.

Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7

J. Luther, R. Fremeau, B. Moyer, 2017, The Journal of Pharmacology and Experimental Therapeutics.

J. Louis, B. H. Manning, N. Gavva, 2008, Journal of Pharmacology and Experimental Therapeutics.